Summary: Bard (C.R.) Inc. Jun 11

  • ID: 1817763
  • June 2011
  • Standard & Poors
1 of 3

The ratings on Murray Hill, N.J.-based C.R. Bard Inc. reflect the company's strong business risk profile and modest financial risk profile. The ratings also overwhelmingly reflect the medical device manufacturer's solid position across several business segments, its cash flow, and strong liquidity. Bard's strong business risk profile is supported by its solid market-share positions across oncology, surgical, urology, and vascular product markets, with a particular strength in urology catheters and specialty access products. The company derives the majority of revenues from products for which it has a No. 1- or No. 2-market share, and the company is not overly reliant on any particular device for its revenues. However, the ratings also reflect potential competitive pressures from other manufacturers and stagnant...

Companies mentioned in this report are: Bard (C.R.) Inc.
Action: Review

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating READ MORE >

Note: Product cover images may vary from those shown
2 of 3

Bard (C.R.) Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.